All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2019-04-23.
From the record
Arbutus Biopharma Corporation's filings since 2017 show 2 warning events of 2 kinds: an auditor change (8-K item 4.01, the latest 2019-04-23); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2017-03-16) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+28.3% a year over 10 filed years; profitable in 0 of 10.
From the record
Arbutus Biopharma Corporation's 10 filed years say what it did: revenue went from $1 million in fiscal 2016 to $14 million in fiscal 2025, up 28.3% a year; it rose in 6 of 9 years; the deepest fall was 84% from fiscal 2022 to fiscal 2024; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Arbutus Biopharma Corporation's shareholder treatment is put at 6.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 32% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -44%: lost 44¢ per shareholder dollar. Leverage 19%: owes 19¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Arbutus Biopharma Corporation lost about 44 cents for every dollar of shareholders' money. Leverage: it owed about 19 cents per dollar of assets, and net share issuance: its share count grew 3.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 36% of 315 in its family; net margin -237.9%.
From the record
Arbutus Biopharma Corporation's standing among 315 graded names in its industry family: revenue of $14 million in fiscal 2025 ranks in the bottom 45% by size; a net margin of -237.9% ranks in the bottom 45%; revenue growth of -28.8% a year over the last 3 filed years ranks in the bottom 18% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 0.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Arbutus Biopharma Corporation's leadership is put at 0.3 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 2% of 415 in its family; the record of its people begins on 2025-03-06 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 1.7 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 45% of 273 in its family for room to expand.
From the record
Arbutus Biopharma Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $18 million against debt of $0 thousand leaves 19% of its assets as net cash, bottom 38% of its family; cash from operations less capital spending is -281.5% of revenue (bottom 41%); research spending of 179.2% of revenue (top 43%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 36% of 306 in its family for growth drivers.
From the record
Arbutus Biopharma Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew -28.8% a year over the last three filed years against 28.3% over all 10, slowing (bottom 11% of its family); the newest year grew 128.3% (top 14%); research spending grew -33.1% a year (bottom 12%) (its annual reports). Arbutus Biopharma Corporation reported 2 product lines in fiscal 2025: Collaboration and Contracts at $13 million (90%), Non Cash Royalty at $1 million (11%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 21% of 233 in its family for expectations against reality.
From the record
Arbutus Biopharma Corporation's newest year against its own record: revenue of $14 million in fiscal 2025 came in 473.5% above the $2 million its prior three years' pace pointed to (top 8% of its family); net income of $34 million against a prior three-year average of $71 million (top 30%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 23%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made